Researchers noted that BNT162b1 is an RNA vaccine that triggers an immune reaction by mimicking the mRNA molecule used through the new SARS-CoV-2 coronavirus to build its infectious proteins.
According to the study, the candidate vaccine is administered intramuscularly and in human cells to produce proteins that are components of the SARS-CoV-2 receptor binding domain, as opposed to the immune formula being trained to produce antibodies.
They stated that these vaccines are sometimes thought to have facilitated the immediate progression of SARS-CoV-2 vaccines.
They said he was one of many applicants for RNA vaccines being studied in parallel to determine their variety in order to move on to a test of their protection and efficacy.
In the ongoing phase 1/2 trial, scientists evaluated the type, side effects and dose of the candidate vaccine in forty-five healthy adults (23 men and 22 non-pregnant women) aged 18 to 55 years.
Participants were randomly assigned to obtain 10 micrograms, 30 or one hundred mg of BNT162b1 or placebo, the study noted.
Participants in the 10 gy 30 g teams also won a momently dose on the 21st, the scientists said.
Based on the study, the researchers stated that BNT162b1 was sometimes well tolerated, some participants had mild to moderate side effects, which increased with the dose level, relative to seven days of vaccination, adding injection site pain, fatigue, headache and fever. sleep disorders.
They said the vaccine caused a “strong immune response” in participants, which increased with the dose level and with an injection.
According to the study, antibodies opposed to SARS-CoV-2 were given 21 days after a singles vaccination at all dose levels, and there is a really extensive accumulation of antibodies that neutralize SARS-CoV-2 seven days after the time 10 or 30 a. doses of -g administered.
He noted that the immune reaction was much more potent in the 30 g organization than in the 10 g organization.
However, the scientists said there were no notable differences in immune response between the 30-μg and 100-μg groups after one dose, and as participants who received the 100-μg dose also experienced greater side effects, they did not receive a second dose.
Participants’ neutralizing antibody grades were reported to be 1.9 to 4.6 times higher than those of patients recovering from SARS-CoV-2 infection.
Although this comparison provides a baseline for comparing vaccine-induced immune reaction and the possibility of the vaccine providing protection, the researchers say that Phase 3 trials are needed to determine the efficacy of BNT162b1.
They said they also recruited adults between the ages of 65 and 85, and added that later stages would prioritize the registration of more varied populations.
Click here to read Mint ePaperLivemint.com is now on Telegram. Join the Livemint channel on your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.